Bleeding risk in IPF patients treated with different anticoagulants:Real world data from the European MultiPartner IPF Registry (EMPIRE)

A. Kolonics-Farkas (Budapest, Hungary), M. Šterclová (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), J. Kus (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Hájková (Bratislava, Slovakia), D. Jovanovic (Belgrade, Republic of Serbia), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Kramer (Petah Tikva, Israel), M. Svoboda (Brno, Czech Republic), M. Janotová (Brno, Czech Republic), M. Vašáková (Prague, Czech Republic)

Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Session: The world of idiopathic pulmonary fibrosis (IPF): global registries
Session type: Poster Discussion
Number: 2205
Disease area: Interstitial lung diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Kolonics-Farkas (Budapest, Hungary), M. Šterclová (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), J. Kus (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Hájková (Bratislava, Slovakia), D. Jovanovic (Belgrade, Republic of Serbia), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Kramer (Petah Tikva, Israel), M. Svoboda (Brno, Czech Republic), M. Janotová (Brno, Czech Republic), M. Vašáková (Prague, Czech Republic). Bleeding risk in IPF patients treated with different anticoagulants:Real world data from the European MultiPartner IPF Registry (EMPIRE). 2205

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: